Skip to main content

Sirturo FDA Approval History

Last updated by Judith Stewart, BPharm on June 25, 2024.

FDA Approved: Yes (First approved December 28, 2012)
Brand name: Sirturo
Generic name: bedaquiline
Dosage form: Tablets
Company: Janssen Research & Development, LLC
Treatment for: Tuberculosis, Resistant

Sirturo (bedaquiline) is an oral diarylquinoline antimycobacterial drug for the treatment of pulmonary multi-drug resistant tuberculosis.

Development timeline for Sirturo

DateArticle
Jun 21, 2024Approval FDA Converts Tuberculosis Treatment Sirturo to Traditional Approval
May 27, 2020Approval FDA Approves New Pediatric Formulation of Sirturo (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
Aug  9, 2019Approval Janssen Announces U.S. FDA Accelerated Approval for Sirturo (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
Aug 17, 2018World Health Organization Recommends the Use of Bedaquiline in all Conventional Multidrug-Resistant Tuberculosis Treatment Regimens
Dec 31, 2012Approval FDA Grants Accelerated Approval for Sirturo to Treat Multi-Drug Resistant Tuberculosis
Sep  5, 2012U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
Jul  2, 2012Janssen Research & Development Submits New Drug Application to FDA for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline (TMC207)

See also

Sirturo (bedaquiline) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer